Fenix Biotech

ACTIVITY Fenix aims to carry out a quick and focused therapeutic study, to validate the use of nano-encapsulated plasmid DNA technology for the treatment of monogenic diseases such as Epidermolysis Bullosa (EB).
TECHNOLOGY

Chitosan encapsulation.
A safe way of delivering correct gene copies to patients suffering monogenic diseases. The nano-encapsulated plasmid is expected to express the proteins that these patients lack, through non-integrative vectors, avoiding major safety concerns.
PRODUCTS/SERVICES
  • Nano-encapsulation technology for treating monogenic disease.
  • Its first indication tested will be Epidermolysis Bullosa.